Invitrogen™ RelB Recombinant Rabbit Monoclonal Antibody (SD07-39)

Description

Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

The NFkB transcription factor was originally identified as a protein complex consisting of a DNA-binding subunit and an associated protein. The DNAbinding subunit is functionally related to c-Rel p75 and Rel B p68. The p50 subunit was initially believed to be a functionally unique protein derived from the amino-terminus of a precursor designated p105. A second protein designated p52 (previously referred to as p49) has been identified that can act as an alternative NFkB subunit. Rel B does not bind with high affinity to NFkB sites, but heterodimers between Rel B and p50 bind with an affinity comparable to that of p50 NFkB homodimers. However, Rel B/p50 heterodimers, in contrast to NFkB heterodimers, transactivates transcription of promotors containing kB binding sites.